Yale scientists identify drug target that may alleviate joint degeneration in osteoarthritis

NewsGuard 100/100 Score

Yale researchers have identified a drug target that may alleviate joint degeneration associated with osteoarthritis, a debilitating condition that afflicts as many as 30 million people in the United States alone, which they report on Jan. 3 in the journal Nature.

Pain relievers and lifestyle changes, such as exercise and reduced excess weight, have long been the therapies most commonly used to treat the joint stiffness and pain caused by degenerative disease, but there is a pressing need for therapies that can prevent joint breakdown that occurs in osteoarthritis.

It is known that specialized proteins known as sodium channels found in cell membranes produce electrical impulses in "excitable" cells within muscles, the nervous system, and the heart. And in previous research, Yale's Stephen G. Waxman identified the key role of one particular sodium channel, called Nav1.7, in the transmission of pain signals.

Now, the labs of Chuan-Ju Liu, the Charles W. Ohse Professor of Orthopedics, and Waxman, the Bridget M. Flaherty Professor of Neurology and professor of neuroscience and pharmacology, both at Yale School of Medicine, have found that the same Nav1.7 channels are also present in non-excitable cells that produce collagen and help maintain the joints in the body.

Osteoarthritis, the most common form of arthritis, is a degenerative disease caused by the breakdown of cartilage that eases friction between the joints. It occurs most commonly in the hands, hips, and knees.

In the new study, the researchers deleted Nav1.7 genes from these collagen-producing cells and significantly reduced joint damage in two osteoarthritis models in mice.

They also demonstrated that drugs used to block Nav1.7 — including carbamazepine, a sodium channel blocker currently used to treat epilepsy and trigeminal neuralgia — also provided substantial protection from joint damage in the mice.

The function of sodium channels in non-excitable cells has been a mystery. This new study provides a window on how small numbers of sodium channels can powerfully regulate the behavior of non-excitable cells."

Stephen G. Waxman, Yale School of Medicine

"The findings open new avenues for disease-modifying treatments," added Wenyu Fu, a research scientist in the Liu laboratory and first author of the study.

Journal reference:

Fu, W., et al. (2024). Nav1.7 as a chondrocyte regulator and therapeutic target for osteoarthritis. Nature. doi.org/10.1038/s41586-023-06888-7.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New study illuminates the genetics of thumb arthritis treatment